Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck Combination Cholesterol Drug Fails to Meet Study Goals; Firm Doesn't Plan to Seek U.S. Approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/20/2012 | 03:17pm CEST
   By Tess Stynes 
 

Merck & Co. (>> Merck & Co., Inc.) said its doesn't plan to seek U.S. Food and Drug Administration for a combination cholesterol treatment that aims to reduce the risk of cardiovascular events after the drug failed to meet primary goals in a large long-term study.

Shares were down 2.9% at $42.40 in premarket trading.

The pharmaceutical giant said it isn't recommending that health-care providers start new patients on the treatment--Tredaptive--an extended release combination of niacin and laropiprant. The company also plans to share the study results with health regulators in countries where it also is approved under the Tredaptive or Cordaptive brands.

"While we are disappointed in these results, we thank the investigators who have conducted the study and the patients who have participated in it," said Peter S. Kim, president, Merck Research Laboratories.

The study that compared extended-release niacin and laropiprant plus statin therapy versus statin therapy included 25,673 patients in Britain, Scandinavia and China considered at risk for cardiovascular issues that were followed for a median 3.9 years.

The study found that the combination drug along with statin therapy didn't significantly further reduce the risk of a combination of cardiovascular events such as nonfatal heart attacks, strokes or coronary-related deaths compared with just statin therapy. There also was an increase in nonfatal events in the group receiving Tredaptive.

Further analysis is under way and detailed study results are expected in the first quarter.

Write to Tess Stynes at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
10/21 MERCK AND : Real-World Study Shows ZEPATIER® (Elbasvir and Grazoprevir) Resulted..
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/19 ONCOSEC MEDICAL : Initiates Registration Directed Clinical Trial, KEYNOTE-695, o..
10/19 MERCK FOUNDATION : Launches Five-Year Initiative to Improve Diabetes Care for Vu..
10/19DJMERCK AND : Chenault Among Few Black CEOs -- WSJ
10/19 BERGENBIO : Announces Start of PhII Trial Assessing Selective AXL Inhibitor BGB3..
10/18DJMERCK AND : Amex Retirement Shines Light on Lack of Diversity in CEO Ranks
10/18 MERCK AND : U.S. FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in M..
10/18 MERCK AND : KEYTRUDA® (pembrolizumab) More Than Doubled Median Overall Survival ..
More news
News from SeekingAlpha
10/21 Stocks to watch next week
10/20 The Market Is Skeptical About Roche Ahead Of Major Trial Read-Outs
10/20 Merck to lay off 1,800 sales reps
10/20 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/19 WHY ARE THESE 6 DOW STOCKS FAIRLY VA : Part 4 Of 5
Financials ($)
Sales 2017 40 270 M
EBIT 2017 13 680 M
Net income 2017 5 793 M
Debt 2017 8 103 M
Yield 2017 2,95%
P/E ratio 2017 31,87
P/E ratio 2018 19,03
EV / Sales 2017 4,53x
EV / Sales 2018 4,45x
Capitalization 174 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 70,0 $
Spread / Average Target 9,5%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY7.88%174 223
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
AMGEN27.41%133 501